Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001175581 | SCV001339214 | uncertain significance | not specified | 2020-03-04 | criteria provided, single submitter | clinical testing | Variant summary: ATRX c.1212G>C (p.Lys404Asn) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 182880 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1212G>C in individuals affected with Mental retardation-hypotonic facies syndrome X-linked, 1 and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Labcorp Genetics |
RCV001345479 | SCV001539599 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2023-09-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001562548 | SCV001785328 | uncertain significance | not provided | 2024-07-12 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001345479 | SCV002087369 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2020-07-17 | no assertion criteria provided | clinical testing |